Pacific Edge Limited (ASX: PEB) - Share Price
Current share price for PEB : $0.210 0.01 (5%)+
Pacific Edge Limited (PEB) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It operates as a global cancer diagnostics organisation focused on development and commercialisation of bladder cancer diagnostic and prognostic tests for individuals presenting with hematuria or under surveillance for recurrent disease. Based in Dunedin, New Zealand, the organisation delivers the Cxbladder test suite through wholly owned CLIA certified laboratories located in New Zealand and the United States.
PEB General Information +
| ASX Code | PEB |
| Website | http://www.pacificedgedx.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 260 |
| PEB Share Price | $0.210 |
| Day High | $0.210 |
| Day Low | $0.210 |
| Last Close | $0.200 |
| PEB Share Price Movement | $0.01 ( 5% ) |
Prices as at 16:40, 31 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Pacific Edge Limited (PEB) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Pacific Edge Limited (PEB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Pacific Edge Limited (PEB) price-sensitive announcements
PEB - Pacific Edge 2026 Annual Shareholders Meeting
Pacific Edge Limited's 2026 Annual Shareholders Meeting highlights key advancements and st
Pacific Edge Limited (PEB)
20 Aug 2026 | 12:08 PM
20 Aug 2026 | 12:08 PM
PEB - Q1 27 Pacific Edge APAC Operations Advance Towards Profit
Pacific Edge Limited's Q1 27 update highlights a stable commercial throughput despite a re
Pacific Edge Limited (PEB)
14 Jul 2026 | 7:30 AM
14 Jul 2026 | 7:30 AM
PEB - PEB Completes Oversubscribed NZ$36.1m Capital Raise
Pacific Edge Limited, a cancer diagnostics company, successfully raised NZ$36.1 million th
Pacific Edge Limited (PEB)
3 Jun 2026 | 7:30 AM
3 Jun 2026 | 7:30 AM
PEB - Retail Offer Reminder
Pacific Edge Limited announced that its Retail Offer, aimed at raising up to NZ$6 million,
Pacific Edge Limited (PEB)
25 May 2026 | 8:26 AM
25 May 2026 | 8:26 AM
Pacific Edge Limited (PEB) Recent ASX Announcements
PEB Financial Summary
| Year to Mar | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$29.83 | -$3.20 | -5.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$27.20 | -$3.40 | 0.30% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$27.09 | -$3.30 | 7.10% | 0.00 | 0.00 | 0.00% | 0.0% |
PEB Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| CSL Limited (CSL) | $82,526M | 0.7309 | -0.4392 | 0.0505 | 10.6756 | 19.0360 | 18.1210 | 2.47% | 2.44% | 2.52% |
| Clinuvel Pharmaceuticals Limited (CUV) | $427M | -0.0696 | -0.0719 | 0.0242 | 12.6796 | 13.6613 | 13.3386 | 0.59% | 0.59% | 0.59% |
| Mesoblast Limited (MSB) | $3,195M | -0.4380 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Pacific Edge Limited (PEB) | $248M | -0.0567 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $5,318M | -1.3893 | 0.0000 | -0.9100 | 0.0000 | 148.3412 | 1,647.3684 | 0.00% | 0.00% | 0.00% |
PEB Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 24.10 | 0.00 |
| Market | 0.37 | 13.40 | 1.17 | 0.80 |
| Sector | 0.64 | 31.40 | 2.63 | 2.61 |
PEB Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Bryan Raymond George Williams | Non-Executive Deputy Chairman, Non-Executive Director | 1 Jan 0001 |
| Mr Tony Barclay | Non-Executive Director | 21 Mar 2022 |
| Mr Anatole Masfen | Non-Executive Director | 1 Jan 0001 |
| Ms Sarah Natalie Park | Non-Executive Director | 1 Jan 0001 |
| Ms Anna Kate Stove | Non-Executive Director | 1 Jan 0001 |
| Mr Mark Green | Non-Executive Director | 1 Jan 0001 |
| Mr Simon Richard Flood | Non-Executive Director, Non-Executive Chairman | 4 Dec 2025 |
Pacific Edge Limited (PEB) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 4 Aug 2023 | WILLIAMS, Bryan | Buy | Indirect Shares | 372,930 | $0.134 | $49,860.740 |
| 21 Apr 2022 | DARLING, David | Issued | Direct Shares | 92,985 | $1.000 | $92,985.000 |
| 2 Dec 2021 | WILLIAMS, Bryan | Buy | Indirect Shares | 40,300 | $1.250 | $50,391.120 |
See all changes in directors' interest & trades for Pacific Edge Limited (PEB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
PEB Management
| Name | Position |
|---|---|
| Peter Meintjes | Chief Executive Officer |
| Grant Edward Gibson | Chief Financial Officer,Company Secretary |
| Tamer Aboushwareb | Chief Medical Officer |
| Darrell Morgan | Chief Operating Officer |
PEB Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Pacific Edge Limited (PEB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 213,547,445 (18.22%) | ANZ New Zealand Investments Limited |
| 130,611,733 (11.14%) | Harbour Asset Management Limited |
| 110,622,815 (10.82%) | FirstCape Group Limited |
PEB Calendar of Events
| Date | Event |
|---|---|
| 24 June 2027 | Report (Annual) |
| 24 May 2027 | Report (Annual) |
| 24 May 2027 | Report (Prelim) |
| 24 November 2026 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
